Japan’s Eisai Boosts Inventory For Possible Flu Pandemic
This article was originally published in PharmAsia News
As a measure to ward off a possible flu pandemic, Eisai maintains three month's worth of drug inventories in three Japanese factories as well as factories in the U.S., Taiwan, China and Indonesia. Eisai also has secured two month's worth of inventories in drug materials, and has initiated a multiple-supplier system. Eisai sells products to over 70 countries and revenue from overseas markets accounts for 60 percent of its sales. President Haruo Naito said that even if stocking inventory costs more, it is necessary to ensure uninterrupted supply. Other companies such as Takeda are also considering taking similar inventory measures and Pfizer has made a manual according to different stages of a pandemic, and set up a system that is able to import drugs from China and the U.S. in a crisis. (Click here for more - Japanese language
You may also be interested in...
Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.
US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.
Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.